Erik C. Emerson - 15 Oct 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: APUS
Reported as of: 15 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Oct 2025, 18:37:52 UTC
Prior SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact

Key filing fact

Erik C. Emerson filed Form 4 for Apimeds Pharmaceuticals US, Inc. (APUS) on 17 Oct 2025.

Key facts

This page summarizes Erik C. Emerson's Form 4 filing for Apimeds Pharmaceuticals US, Inc. (APUS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Oct 2025, 18:37.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001710496 Primary reporting owner

Emerson Erik C.

Relationship: Chief Executive Officer, Director
Address: C/O APIMEDS PHARMACEUTICALS US, INC., 100 MATAWAN ROAD, SUITE 325, MATAWAN
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Signature date: 17 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APUS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +215,000
Change %
Price: $0.000000
Shares after: 215,000
Date: 15 Oct 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 215,000
Exercise price: $1.92
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.